A research team has discovered a new mechanism and drug combination strategy that can effectively treat osteoporosis, a ...

Osteogenesis imperfecta (OI) refers to a group of rare genetic bone disorders that results in the formation of fragile bones. In patients with OI, the matrix that makes up the bone has been found to ...

Studies by University of Birmingham researchers suggest that a naturally occurring peptide known as PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration), could represent a promising potential ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

Around 40% of adults worldwide are affected by osteopenia: a loss of bone mineral density. This condition is extremely common ...

Periodontitis is characterized by the loss of teeth resulting from inflammation of gums due to bacterial infections. The susceptibility to such bone loss disorders increases with age. The expression ...

Scientists have identified a little-known receptor, GPR133, as a powerful regulator of bone strength. By activating it with a newly discovered compound called AP503, they were able to boost bone ...

Anabolic agents work differently from other osteoporosis medications in that they don't just slow down bone loss — they can trigger the growth of new bone.

The investigators closed their report by explaining that while therapies like tenapanor and SNF472 have shown promise, and ...